Full-Time
Posted on 7/2/2025
Specializes in eye care products and solutions
No salary listed
Expert
Frankfurt, Germany
In Person
Alcon specializes in eye care products and vision solutions aimed at improving people's quality of life through better vision. Their product offerings include solutions for cataract surgery, retinal health, and contact lenses. Alcon's products work by utilizing advanced technology and research to provide effective treatments and products for eye care professionals and consumers. What sets Alcon apart from its competitors is its strong emphasis on research and development, ensuring they remain leaders in the eye care industry. The company's goal is to enhance vision and overall quality of life while promoting a diverse and inclusive workplace.
Company Size
10,001+
Company Stage
IPO
Headquarters
Geneva, Switzerland
Founded
1945
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, & vision coverage
HSA Medical Plan
PTO
Paid Parental leave
401k
Retirement Plan Company Contribution
Low payroll deductions
Tuition Reimbursement Program
Annual Bonus
Free Family Contact Lens Program
12 Company Paid Holidays
Alcon announced its intention to acquire LumiThera and its PBM device for the treatment of early and intermediate dry AMD.
Alcon, the Geneva-headquartered eyecare company, has announced plans to acquire LumiThera, a US firm that is working on a multi-wavelength treatment for dry age-related macular degeneration (AMD).
FORT WORTH, July 8, 2025 - Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Julie M. Brewer will join the company and its Executive Leadership Team as Senior Vice President, President, Global Franchises, effective July 9.
Alcon is continuing its trend of acquisitions in 2025 with the recent announcement that the company will acquire LumiThera, Inc. and its photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD).
Alcon has also announced its intention to launch acoltremon ophthalmic solution in the US during the third quarter of 2025 and anticipates bringing it to other markets in the future.